Clinical Operations in Oncology Trials Europe 2022

Clinical Operations in Oncology Trials Europe 2022 APICES is actively participating in the upcoming CLINICAL OPERATIONS IN ONCOLOGY TRIALS EUROPE 2022 congress in Zurich. In the following link you can access the agenda. Clinical Operations in Oncology Trials Europe 2022 On November 23rd, Ana Moreno, Director Global Clinical Operations at APICES, will give us her…

First Congress Fundación Española de Tratamiento de Tumores de Cabeza y Cuello

First Congress Fundación Española de Tratamiento de Tumores de Cabeza y Cuello It is a pleasure for APICES to cooperate with this multidisciplinary congress in head and neck cancer where clinical research is a must. Congrats to organisers, speakers, sponsors and attendees. Inicio – I Congreso de la FETTCC (fundacionttcc.com)

Acknowledgement for APICES collaboration in study ABIDO published in ” European Journal of Cancer”

Acknowledgement for APICES collaboration in study ABIDO published in ” European Journal of Cancer” This month, we want to share the acknowledgment that APICES has received in the recent publication titled “A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate…

Acknowledgement for APICES collaboration in DERMIA study published in “Supportive Care in Cancer”

Acknowledgement for APICES collaboration in DERMIA study published in “Supportive Care in Cancer” This month, we want to share the acknowledgment that APICES has received in the recent publication titled “A phase 2 study for evaluating doxycycline 50 mg once daily and 100 mg once daily as preemptive treatment for skin toxicity in patients with…

Acknowledgement for APICES collaboration in ABACUS trial published in “European Urology”

Acknowledgement for APICES collaboration in ABACUS trial published in “European Urology” Once more time we are privileged to share the acknowledgment that APICES has received in the recent publication titled: “Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder”. This is an extra motivation for the whole APICES team.…